Document Detail

Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B.
MedLine Citation:
PMID:  17237999     Owner:  NLM     Status:  MEDLINE    
We sought to evaluate the long-term results of interferon-alpha (IFN-alpha) therapy in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. Eighty HBeAg-negative naive patients (62 men; mean age, 39.9 years) who received IFN-alpha for 6 months were studied. Alanine aminotransferase normalization with undetectable HBV-DNA by molecular hybridization was accepted as response. All patients but 1 were precirrhotic stage. At the end of treatment, 44 (55%) patients responded, and they were followed for a mean of 59.5 months (range, 18-132). Twenty-seven patients (61.4%) showed recurrence (63% in first year). Responses at 6 months and at the end of the follow-up period 42.5% and 30% (including 7 patients without end treatment response), respectively. Recurrence of HBV replication was not detected after the 2-years follow-up period. Histologic improvement was observed in 83.3% patients with end-of-follow-up response. HBsAg became negative in 4 patients (5%). On multivariate analysis, younger age (P = .04) and lower GGT level (P = .037) were independent factors for prediction of end-of-follow-up response. Nearly half of the patients with HBeAg-negative chronic hepatitis B responds to IFN-alpha at the end of therapy. Despite the high recurrence rates, response continues in about one third of patients after a mean of 59.5 months.
Sabahattin Kaymakoglu; Ahmet Danalioglu; Kadir Demir; Cetin Karaca; Filiz Akyuz; Derya Onel; Selim Badur; Ugur Cevikbas; Fatih Besisik; Yilmaz Cakaloglu; Atilla Okten
Related Documents :
9651559 - Efficacy and safety of systemic recombinant interferon-alpha in behçet's disease.
20691049 - Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 malaw...
11177479 - The absence of hyperbilirubinaemia is highly predictive of treatment failure in advance...
18778199 - Peg-interferon alpha-2a versus peg-interferon alpha-2b in nonresponders with hcv active...
24238059 - Timing of symptom improvement after parathyroidectomy for primary hyperparathyroidism.
18197359 - Change over time of mortality predictors after haart initiation in a senegalese cohort.
19726489 - Quality of life in patients with severe malocclusion before treatment.
7068729 - The geometric knee replacement in polyarthritis.
23084729 - Does knee joint proprioception alter following medial patellofemoral ligament reconstru...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Digestive diseases and sciences     Volume:  52     ISSN:  0163-2116     ISO Abbreviation:  Dig. Dis. Sci.     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-04-10     Completed Date:  2007-05-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902782     Medline TA:  Dig Dis Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  727-31     Citation Subset:  AIM; IM    
Department of Gastroenterohepatology, Istanbul Medical Faculty, Istanbul University, Capa 34390, Istanbul, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / therapeutic use*
DNA, Viral / analysis
Hepatitis B e Antigens*
Hepatitis B virus / immunology
Hepatitis B, Chronic / drug therapy*,  immunology
Interferon Alfa-2a / therapeutic use
Interferon Alfa-2b / therapeutic use
Interferon-alpha / therapeutic use*
Retrospective Studies
Treatment Outcome
Reg. No./Substance:
0/Antiviral Agents; 0/DNA, Viral; 0/Hepatitis B e Antigens; 0/Interferon-alpha; 76543-88-9/Interferon Alfa-2a; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of D-xylose hydrogen breath test with urinary D-xylose test in Indian children with celia...
Next Document:  A new method of spatio-temporal topographic mapping by correlation coefficient of K-means cluster.